Johnson & Johnson Proposes $5.5 Billion Settlement to Resolve Talc Lawsuits

Johnson & Johnson is making a new attempt to resolve the massive litigation over its talc-based products, proposing a settlement valued at a minimum of $5.5 billion. The offer aims to end tens of thousands of lawsuits from plaintiffs who allege the company's baby powder and other talc products caused ovarian cancer.

A New Strategy After Failed Bankruptcies

This proposal marks a significant shift from J&J's previous efforts, which involved three unsuccessful attempts to use bankruptcy proceedings to manage the liabilities. In those cases, J&J created a subsidiary, transferred the talc-related legal risks to it, and then filed for bankruptcy. Courts repeatedly rejected this strategy, which was opposed by plaintiffs who argued a financially healthy company should not use bankruptcy protections.

Unlike the bankruptcy plans, the new settlement is a voluntary process that does not require court approval to bind unwilling participants. According to plaintiffs' lawyers cited by Reuters, this approach would also ensure claimants are paid much faster, with full payouts expected in less than two years compared to the 25-year timeline proposed in the bankruptcy settlement.

Terms and Outlook

Ad

The settlement's success hinges on broad acceptance from the plaintiffs. According to the company, the deal will only proceed if it is accepted by enough claimants to cover 95% of the approximately 76,000 ovarian cancer claims. Both J&J and leading plaintiffs' law firms have expressed confidence that the threshold can be met.

Analysts suggest plaintiffs may be more inclined to accept this offer following a recent federal court ruling that tightened the standards for scientific evidence admissible in court. This development potentially weakens the legal standing of some claims, making a settlement more attractive than the uncertainty of a trial.

Remaining Legal Exposure

While the proposed settlement would resolve the vast majority of current ovarian cancer claims, it does not eliminate all future legal risk for Johnson & Johnson. The agreement is not designed to cover claims from individuals who may be diagnosed with ovarian cancer in the future and decide to sue the company. This leaves a long-term liability tail, a risk J&J had previously sought to cap entirely through its bankruptcy strategy.